Skeletal muscle wasting in cachexia and sarcopenia: Molecular pathophysiology and impact of exercise training

Journal of Cachexia, Sarcopenia and Muscle

Volumn 1, Issue 1, 2010, Pages 9-21

  Lenk, Karsten ^a   Schuler, Gerhard ^a   Adams, Volker ^a  

^a UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

Author keywords

Cachexia; Exercise training; Muscle wasting disease; Sarcopenia

Indexed keywords

3 NITROTYROSINE; ADENOSINE TRIPHOSPHATE; ANABOLIC AGENT; CALCIUM; CALPAIN; CALPASTATIN; CASPASE; CATHEPSIN L; ESTROGEN; GAMMA INTERFERON; HYDROXYL RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; MAMMALIAN TARGET OF RAPAMYCIN; MUSCLE PROTEIN; MYOD PROTEIN; MYOGENIC FACTOR 5; MYOGENIN; PEROXYNITRITE; PROTEASOME; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; S6 KINASE; SOMATOMEDIN; TESTOSTERONE; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNINDEXED DRUG;

AUTOPHAGY; BREATHING; CACHEXIA; CELL DEATH; CELL MEMBRANE; CELL PROLIFERATION; CELL REGENERATION; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DNA FRAGMENTATION; EXERCISE; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; LOCOMOTION; LYSOSOME; MOLECULAR PATHOLOGY; MUSCLE ATROPHY; MUSCLE CELL; MUSCLE GROWTH; MYOPATHY; NEOPLASM; NONHUMAN; OXIDATIVE PHOSPHORYLATION UNCOUPLING; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; STRENGTH; TUMOR GROWTH; UPREGULATION;

EID: 79958137426     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-010-0007-1     Document Type: Review

References (143)

1. Carmeli E, Coleman R, Reznick AZ. The biochemistry of aging muscle. Exp Gerontol. 2002; 37: 477-89.
2. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998; 147: 755-63.
3. Tzankoff SP, Norris AH. Effect of muscle mass decrease on age-related BMR changes. J Appl Physiol. 1977; 43: 1001-6.
4. Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism. 1970; 19: 653-63.
5. Evans WJ, Morley JE, Argiles J, Bales C, Baracos V, Guttridge D, et al. Cachexia: a new definition. Clin Nutr. 2008; 27: 793-9.
6. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006; 83: 735-43.
7. Lum JJ, DeBerardinis RJ, Thompson CB. Autophagy in metazoans: cell survival in the land of plenty. Nat Rev Mol Cell Biol. 2005; 6: 439-48.
8. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, et al. FOXO transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117: 399-412.
9. Mammucari C, Milan G, Romanello V, Masiero E, Rudolf R, Del Piccolo P, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab. 2007; 6: 458-71.
10. Dodd SL, Gagnon BJ, Senf SM, Hain BA, Judge AR. Ros-mediated activation of NF-kappaB and Foxo during muscle disuse. Muscle Nerve. 2010; 41: 110-3.
11. Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer. 2001; 85: 297-302.
12. Sandri M, Lin J, Handschin C, Yang W, Arany ZP, Lecker SH, et al. PGC-1α{pipe} protects skeletal muscle from atrophy by suppressing FoxO3 action and atrophy-specific gene transcription. Proc Natl Acad Sci USA. 2006; 103: 16260-5.
13. Glass DJ. Signaling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat Cell Biol. 2003; 5: 87-90.
14. Guttridge DC. Signaling pathways weigh in on decisions to make or to break skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004; 7: 443-50.
15. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 1996; 335: 1897-905.
16. Bardag-Gorce F, Farout L, Veyrat-Durebex C, Briand Y, Briand M. Changes in 20 S proteasome activity during ageing of the LOU rat. Mol Biol Rep. 1999; 26: 89-93.
17. Clavel S, Coldefy AS, Kurkdjian E, Salles J, Margarites I, Derijard B. Atrophy-related ubiquitin ligases, atrogin-1 and MuRF1 are up-regulated in aged rat Tibialis Anterior muscle. Mech Ageing Dev. 2006; 127: 794-801.
18. Raue U, Slivka D, Jemiolo B, Hollon C, Trappe S. Proteolytic gene expression differs at rest and after resistance exercise between young and old women. J Gerontol A Biol Sci Med Sci. 2007; 62: 1407-12.
19. DeRuisseau KC, AN KAVAZIS, Powers SK. Selective downregulation of ubiquitin conjugation cascade mRNA occurs in the senescent rat soleus muscle. Exp Gerontol. 2005; 40: 526-31.
20. Edström E, Altun M, Hägglund M, Ulfhake B. Increased muscle proteasome activity correlates with disease severity in gastric cancer patients. J Gerontol A Biol Sci Med Sci. 2006; 61: 663-74.
21. Du XL, Sui GZ, Stockklauser-Farber K, Weiss J, Zink S, Schwippert B, et al. Introduction of apoptosis by high proinsulin and glucose in cultured human umbilical vein endothelial cells is mediated by reactive oxygen species. Diabetologia. 1998; 41: 249-56.
22. Bossola M, Pacelli F, Costelli P, Tortorelli A, Rosa F, Doglietto G. Proteasome activities in the rectus abdominis muscle of young and older individuals. Biogerontology. 2008; 9: 261-8.
23. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003; 83: 731-801.
24. Wendt A, Thompson VF, Goll DE. Interaction of calpastatin with calpain: a review. Biol Chem. 2004; 385: 465-72.
25. Dargelos E, Brule C, Combaret L, Hadj-Sassi A, Dulong S, Poussard S, et al. Involvement of the calcium-dependent proteolytic system in skeletal muscle aging. Exp Gerontol. 2007; 42: 1088-98.
26. Pattison JS, Folk LC, Madsen RW, Childs TE, Booth FW. Transcriptional profiling identifies extensive downregulation of extracellular matrix gene expression in sarcopenic rat soleus muscle. Physiol Genomics. 2003; 15: 34-43.
27. O'Connell K, Gannon J, Doran P, Ohlendieck K. Proteomic profiling reveals a severely perturbed protein expression pattern in aged skeletal muscle. Int J Mol Med. 2007; 20: 145-53.
28. Musaro A, McCullagh K, Paul A, Houghton L, Dobrowolny G, Molinaro M, et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat Genet. 2001; 27: 195-200.
29. Dennis RA, Przybyla B, Gurley C, Kortebein PM, Simpson P, Sullivan DH, et al. Aging alters gene expression of growth and remodeling factors in human skeletal muscle both at rest and in response to acute resistance exercise. Physiol Genomics. 2008; 32: 393-400.
30. Welle S, Bhatt K, Shah B, Thornton CA. Insulin-like growth factor-1 and myostatin mRNA expression in muscle: comparison between 62-77 and 21-31 year old men. Exp Gerontol. 2002; 37: 833-9.
31. Williams A, Sun X, Fischer JE, Hasselgren PO. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery. 1999; 126: 744-9.
32. Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos VE, Bailey J, et al. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 2004; 18: 39-51.
33. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004; 114: 370-8.
34. Liu CM, Yang Z, Liu CW, Wang R, Tien P, Dale R, et al. Effect of RNA oligonucleotide targeting Foxo-1 on muscle growth in normal and cancer cachexia mice. Cancer Gene Ther. 2007; 14: 945-52.
35. Jagoe RT, Redfern CP, Roberts RG, Gibson GJ, Goodship TH. Skeletal muscle mRNA for cathepsin B but not components of the ubiquitin-proteasome pathway are increased in patients with lung cancer referred for thoracotomy. Clin Sci. 2002; 102: 353-61.
36. Costelli P, Muscaritoli M, Bossola M, Penna F, Reffo P, Bonetto A, et al. IGF-1 is downregulated in experimental cancer cachexia. Am J Physiol Regul Integr Comp Physiol. 2006; 291: R674-83.
37. Schulze PC, Fang J, Kassik KA, Gannon J, Cupesi M, MacGillivray C, et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitin-mediated muscle atrophy in chronic left ventricular dysfunction. Circ Res. 2005; 97: 418-26.
38. Eley HL, Russell ST, Tisdale MJ. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J. 2007; 407: 113-20.
39. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest. 1996; 97: 2016-2509.
40. Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J. 1996; 15: 1753-65.
41. Li YP, Schwartz RJ, Wadell ID, Holloway BR, Reid MB. Skeletal muscle myocytes undergo protein loss and reactive oxygen-mediated NFkB activation in response to tumor necrosis factor a. FASEB J. 1998; 12: 871-80.
42. Laviano A, Meguid MM, Preziosa I, Fanelli FR. Oxidative stress and wasting in cancer. Curr Opin Clin Nutr Metab Care. 2007; 10: 449-56.
43. Li YP, Chen Y, Li AS, Reid MB. Hydrogen peroxide stimulates ubiquitin-conjugating activity and expression of genes for specific E2 and E3 proteins in skeletal muscle myotubes. Am J Physiol Cell Physiol. 2003; 285: C806-12.
44. Gomes-Marcondes MC, Tisdale MJ. Induction of protein catabolism and the ubiquitin-proteasome pathway by mild oxidative stress. Cancer Lett. 2002; 180: 69-74.
45. 2-mediated oxidative stress in differentiated C2C12 myotubes. Life Sci. 2009; 84: 468-81.
46. Harman D. Aging: a theory based on free radical and radiation chemistry. J Gerontol. 1956; 11: 298-300.
47. Sohal RS, Weindruch R. Oxidative stress, caloric restriction, and aging. Science. 1996; 273: 59-63.
48. Feng J, Xie H, Meany DL, Thompson LV, Arriaga EA, Griffin TJ. Quantitative proteomic profiling of muscle type-dependent and age-dependent protein carbonylation in rat skeletal muscle mitochondria. J Gerontol A Biol Sci Med Sci. 2010; 63: 1137-52.
49. Howard C, Ferrucci L, Sun K, Fried LP, Walston J, Varadhan R, et al. Oxidative protein damage is associated with poor grip strength among older women living in the community. J Appl Physiol. 2007; 103: 17-20.
50. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids. 2003; 25: 295-311.
51. Barreiro E, Coronell C, Lavina B, Ramirez-Sarmiento A, Orozco-Levi M, Gea J. Aging, sex differences, and oxidative stress in human respiratory and limb muscles. Free Radic Biol Med. 2006; 41: 797-809.
52. Fugere NA, Ferrington DA, Tompson LV. Protein nitration with aging in the rat semimembranosus and soleus muscles. J Gerontol A Biol Sci Med Sci. 2006; 61: 806-12.
53. Thompson LV, Durand D, Fugere NA, Ferrington DA. Myosin and actin expression and oxidation in aging muscle. J Appl Physiol. 2006; 101: 1581-7.
54. Kanski J, Hong SJ, Schoeneich C. Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J Biol Chem. 2005; 280: 24261-6.
55. Donoghue P, Staunton L, Mullen E, Manning G, Ohlendieck K. DIGE analysis of rat skeletal muscle proteins using nonionic detergent phase extraction of young adult versus aged gastrocnemius tissue. J Proteomics. 2010; 73: 1441-53.
56. Barreiro E, de la Puente B, Busquets S, Lopez-Soriano FJ, Gea J, Argiles JM. Both oxidative and nitrosative stress are associated with muscle wasting in tumour-bearing rats. FEBS Lett. 2005; 579: 1646-52.
57. Mantovani G, Maccio A, Madeddu C, Mura L, Gramignano G, Lusso M, et al. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. J Mol Med. 2003; 81: 664-73.
58. Levine B, Kalman J, Mayer L, Fillit HM, Packer MP. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323: 236-41.
59. Guttridge DC, Mayo MW, Madrid LV, Wang CY, Baldwin Jr AS. NF-kappa B-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science. 2000; 289: 2363-6.
60. Li YP, Reid MB. NF-kB mediates the protein loss induced by TNF-α in differentiated skeletal muscle. Am J Physiol. 2000; 279: R1165-70.
61. Adams V, Linke A, Wisloff U, Doring C, Erbs S, Krankel N, et al. Myocardial expression of Murf-1 and MAFbx after induction of chronic heart failure: effect on myocardial contractility. Cardiovasc Res. 2007; 73: 120-9.
62. Li YP, Chen Y, John J, Moylan J, Jin B, Mann DL, et al. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J. 2005; 19: 362-70.
63. Adams V, Mangner N, Gasch A, Krohne C, Gielen S, Hirner S, et al. Induction of MuRF1 Is essential for TNF-[alpha]-induced loss of muscle function in mice. J Mol Biol. 2008; 384: 48-59.
64. Tisdale MJ. BIOMEDICINE: protein loss in cancer cachexia. Science. 2000; 289: 2293-4.
65. Schaap LA, Pluijm SMF, Deeg DJH, Harris TB, Kritchevsky SB, Newman AB, et al. Higher inflammatory marker levels in older persons: associations with 5-year change in muscle mass and muscle strength. J Gerontol A Biol Sci Med Sci. 2009; 64A: 1183-9.
66. Rieu I, Magne H, Savary-Auzeloux I, Averous J, Bos C, Peyron MA, et al. Reduction of low grade inflammation restores blunting of postprandial muscle anabolism and limits sarcopenia in old rats. J Physiol. 2009; 587: 5483-92.
67. Balage M, Averous J, Remond D, Bos C, Pujos-Guillot E, Papet I, et al. Presence of low-grade inflammation impaired postprandial stimulation of muscle protein synthesis in old rats. J Nutr Biochem. 2010; 21: 325-31.
68. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev. 1999; 19: 223-48.
69. Llovera M, Garcia-Martinez C, Lopez-Soriano J, Carbo N, Agell N, Lopez-Soriano FJ, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 1998; 142: 183-9.
70. Adams V, Nehrhoff B, Späte U, Linke A, Schulze PC, Baur A, et al. Induction of iNOS-expression in skeletal muscle by IL-1β and NFκβ activation: an in vitro and in vivo study. Cardiovasc Res. 2002; 54: 95-104.
71. Ungureanu-Longrois D, Balligand JL, Kelly RA, Smith TW. Myocardial contractility dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol. 1995; 27: 155-67.
72. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol. 1961; 9: 493-5.
73. DEcary S, Mouly V, Hamida CB, Sautet A, Barbet JP, Butler-Browne GS. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy. Hum Gene Ther. 1997; 8: 1429-38.
74. Olson EN, Klein WH. bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes Dev. 1994; 1: 1-8.
75. Megeney LA, Kablar B, Garrett K, Anderson JE, Rudnicki MA. MyoD is required for myogenic stem cell function in adult skeletal muscle. Genes Dev. 1996; 10: 1173-83.
76. Tintignac LA, Lagirand J, Batonnet S, Sirri V, Leibovitch MP, Leibovitch SA. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase. J Biol Chem. 2005; 280: 2847-56.
77. McCroskery S, Thomas M, Platt L, Hennebry A, Nishimura T, McLeay L, et al. Improved muscle healing through enhanced regeneration and reduced fibrosis in myostatin-null mice. J Cell Sci. 2005; 118: 3531-41.
78. McFarlane C, Hennebry A, Thomas M, Plummer E, Ling N, Sharma M, et al. Myostatin signals through Pax7 to regulate satellite cell self-renewal. Exp Cell Res. 2008; 314: 317-29.
79. Seale P, Sabourin LA, Girgis-Gabardo A, Mansouri A, Gruss P, Rudnicki MA. Pax7 is required for the specification of myogenic satellite cells. Cell. 2000; 102: 777-86.
80. Zaccagnini G, Martelli F, Magenta A, Cencioni C, Fasanaro P, Nicoletti C, et al. p66ShcA and oxidative stress modulate myogenic differentiation and skeletal muscle regeneration after hind limb ischemia. J Biol Chem. 2007; 282: 31453-9.
81. Adams V, Gielen S, Hambrecht R, Schuler G. Apoptosis in skeletal muscle. Front Biosci. 2001; 6: d1-d11.
82. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest. 2004; 113: 115-23.
83. Argiles JM, Lopez-Soriano FJ, Busquets S. Apoptosis signalling is essential and precedes protein degradation in wasting skeletal muscle during catabolic conditions. Int J Biochem Cell Biol. 2008; 40: 1674-8.
84. Snow MH. The effects of aging on satellite cells in skeletal muscles of mice and rats. Cell Tissue Res. 1977; 185: 399-408.
85. Gibson MC, Schultz E. Age-related differences in absolute numbers of skeletal muscle satellite cells. Muscle Nerve. 1983; 6: 574-80.
86. Kadi F, Charifi N, Denis C, Lexell J. Satellite cells and myonuclei in young and elderly women and men. Muscle Nerve. 2004; 20: 120-7.
87. Brooks NE, Schuenke MD, Hikida RS. No change in skeletal mucle satellite cells in young and aging rat soleus muscle. J Physiol Sci. 2009; 59: 465-71.
88. Roth SM, Martel GF, Ivey FM, Lemmer JT, Metter EJ, Hurley BF, et al. Skeletal muscle satellite cell populations in healthy young and older men and women. Anat Rec. 2000; 260: 351-8.
89. Leiter JRS, Anderson JE. Satellite cells are increasingly refractory to activation by nitric oxide and stretch in aged mouse-muscle cultures. Int J Biochem Cell Biol. 2010; 42: 132-6.
90. Fulle S, Di Donna S, Puglielli C, Pietrangelo T, Beccafico S, Bellomo R, et al. Age-dependent imbalance of the antioxidative system in human satellite cells. Exp Gerontol. 2005; 40: 189-97.
91. Haddad F, Adams GR. Aging-sensitive cellular and molecular mechnisms associated with skeletal muscle hypertroph. J Appl Physiol. 2006; 100: 1188-203.
92. Kawada S, Tachi C, Ishii N. Content and localization of myostatin in mouse skeletal muscles during aging, mechanical unloading and reloading. J Muscle Res Cell Motil. 2001; 22: 627-33.
93. Leger B, Derave W, DeBock K, Hespel P, Russell AP. Human sarcopenia reveals an increase in SOCS-3 and myostatin and reduced efficiency of Akt phosphorylation. Rejuvenation Res. 2008; 11: 163-75.
94. Baumann AP, Ibebunjo C, Grasser WA, Paralker VM. Myostatin expression in age and denervation-induced skeletal muscle atrophy. J Musculoskelet Neuronal Interact. 2003; 3: 8-16.
95. Chabi B, Ljubicic V, Menzies KJ, Saleem A, Hood DA. Mitochondrial function and apoptotic susceptibility in aging skeletal muscle. Aging Cell. 2008; 7: 2-12.
96. Rice KM, Blough ER. Sarcopenia-related apoptosis is regulated differently in fast-and slow-twitch muscles of the aging F344/N × BN rat model. Mech Ageing Dev. 2006; 127: 670-9.
97. Wohlgemuth SE, Seo AY, Marzetti E, Lees HA, Leeuwenburgh C. Skeletal muscle autophagy and apoptosis during aging: effects of calorie restriction and life-long exercise. Exp Gerontol. 2010; 45: 138-48.
98. Marzetti E, Wohlgemuth SE, Lees HA, Chung HY, Giovannini S, Leeuwenburgh C. Age-related activation of mitochondrial caspase-independent apoptotic signaling in rat gastrocnemius muscle. Mech Ageing Dev. 2008; 129: 542-9.
99. Musaro A, Giacinti C, Borsellino G, Dobrowolny G, Pelosi L, Cairns L, et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proc Natl Acad Sci USA. 2004; 101: 1206-10.
100. Benny Klimek ME, Aydogdu T, link MJ, Pons M, Koniaris LG, Zimmers TA. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia. Biochem Biophys Res Commun. 2010; 391: 1548-54.
101. Bonetto A, Penna F, Minero VG, Reffo P, Bonelli G, Baccino FM, et al. Deacetylase inhibitors modulate myostatin/follistatin axis without improving cachexia in tumor-bearing mice. Curr Cancer Drug Targets. 2009; 9: 608-19.
102. van Royen M, Carbo N, Busquets S, Alvarez B, Quinn LS, Lopez-Soriano FJ, et al. DNA fragmentation occurs in skeletal muscle during tumor growth: a link with cancer cachexia? Biochem Biophys Res Commun. 2000; 270: 533-7.
103. Busquets S, Deans C, Figueras M, Moore-Carrasco R, Lopez-Soriano FJ, Fearon KCH, et al. Apoptosis is present in skeletal muscle of cachectic gastro-intestinal cancer patients. Clin Nutr. 2007; 26: 614-8.
104. Belizario JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1, -3, -6, -8 and -9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer. 2001; 84: 1135-40.
105. Bassel-Duby R, Olson EN. Signaling pathways in skeletal muscle remodeling. Annu Rev Biochem. 2006; 75: 19-37.
106. Storer TW, Magliano L, Woodhouse L, Lee ML, Dzekov C, Dzekov J, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab. 2003; 88: 1478-85.
107. Sinha-Hikim I, Artaza J, Woodhouse L, Gonzalez-Cadavid N, Singh AB, Lee MI, et al. Testosterone-induced increase in muscle size in healthy young men is associated with muscle fiber hypertrophy. Am J Physiol Endocrinol Metab. 2002; 283: E154-64.
108. Kenny AM, Prestwood KM, Gruman CA, Marcello KM, Raisz LG. Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels. J Gerontol. 2001; 56: M266-72.
109. Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Lenrow DA, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab. 1999; 84: 2647-53.
110. Sih R, Morley JE, Kaiser FE, Perry III HM, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab. 1997; 82: 1661-7.
111. Bakhshi V, Elliott M, Gentili A, Godschalk M, Mulligan T. Testosterone improves rehabilitation outcomes in ill older men. J Am Geriatr Soc. 2000; 48: 550-3.
112. Tenover JL. Testosterone replacement therapy in older adult men. Int J Androl. 1999; 22: 300-6.
113. Clague JE, Wu FC, Horan MA. Difficulties in measuring the effects of testosterone replacement therapy on muscle function in older men. Int J Androl. 1999; 22: 261-5.
114. Brill KT, Weltman AL, Gentili A, Patrie JT, Fryburg DA, Hanks JB, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expression in healthy older men. J Clin Endocrinol Metab. 2002; 87: 5649-57.
115. Urban RJ, Bodenburg YH, Gilkison C, Foxworth J, Coggan AR, Wolfe RR, et al. Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis. Am J Physiol Endocrinol Metab. 1995; 269: E820-6.
116. Ferrando AA, Sheffield-Moore M, Yeckel CW, Gilkison C, Jiang J, Achacosa A, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab. 2002; 282: E601-7.
117. Chlebowski RT, Heber D. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res. 1982; 42: 2495-8.
118. Zitzmann M, Nieschlag E. Hormone substitution in male hypogonadism. Mol Cell Endocrinol. 2000; 161: 73-88.
119. Lobo RA. Androgens in postmenopausal women: production, possible role, and replacement options. Obstet Gynecol Surv. 2001; 56: 361-76.
120. Hein L, Barsh GS, Bratt RE, Dzau VJ, Koblika BK. Behavioural and cardiovascular effects of disrupting the angiotensin II type-2-receptor gene in mice. Nature. 1995; 377: 744-7.
121. Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, et al. Hypogonadism in male patients with cancer. Cancer. 2006; 106: 2583-91.
122. Jones TE, Stephenson KW, King JG, Knight KR, Marshall TL, Scott WB. Sarcopenia-mechanisms and treatments. J Geriatr Phys Ther. 2009; 32: 39-45.
123. Mock V, Dow KH, Meares CJ, Grimm PM, Dienemann JA, Haisfield-Wolfe ME, et al. Effects of exercise on fatigue, physical functioning, and emotional distress during radiation therapy for breast cancer. Oncol Nurs Forum. 1997; 24: 991-1000.
124. Dimeo FC, Stieglitz RD, Novello-Fischer U, Fetscher S, Keul J. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999; 85: 2273-7.
125. Nieman DC, Cook VD, Henson DA, Suttles J, Rejeski WJ, Ribisl PM, et al. Moderate exercise training and natural killer cell cytotoxic activity in breast cancer patients. Int J Sports Med. 1995; 16: 334-7.
126. Deuster PA, Morrison SD, Ahrens RA. Endurance exercise modifies cachexia and tumor growth in rats. Med Sci Sports Exerc. 1985; 17: 385-92.
127. Daneryd P, Hafstroem L, Svanberg E, Karlberg I. Insulin sensitivity, hormonal levels and skeletal muscle protein metabolism in tumour-bearing exercising rats. Eur J Cancer. 1995; 31A: 97-103.
128. Courneya KS, Segal RJ, Mackey JR, Gelmon K, Reid RD, Friedenreich CM, et al. Effects of aerobic and resistance exercise in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial. J Clin Oncol. 2007; 25: 4396-404.
129. Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomark Prev. 2005; 14: 1672-80.
130. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003; 21: 1653-9.
131. Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006; 38: 2045-52.
132. Mueller M, Breil FA, Vogt M, Steiner R, Lippuner K, Popp A, et al. Different response to eccentric and concentric training in older men and women. Eur J Appl Physiol. 2009; 107: 145-52.
133. van Helvoort HA, Heijdra YF, Thijs HM, Vina J, Wanten GL, Dekhuijzen PN. Exercise-induced systemic effects in muscle-wasted patients with COPD. Med Sci Sports Exerc. 2006; 38: 1543-52.
134. Galvao DA, Nosaka K, Taaffe DR, Peake J, Spry N, Suzuki K, et al. Endocrine and immune response to resistance training in prostate cancer patients. Prostate Cancer Prostatic Dis. 2008; 11: 160-5.
135. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL- 6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood. 1990; 75: 40-7.
136. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha; production in humans. FASEB J. 2003; 17: 884-6.
137. Linke A, Adams V, Schulze PC, Erbs S, Gielen S, Fiehn E, et al. Antioxidative effects of exercise training in patients with chronic heart failure. Increase in radical scavenger enzyme activity in skeletal muscle. Circulation. 2005; 111: 1763-70.
138. Fujita S, Abe T, Drummond MJ, Cadenas JG, Dreyer HC, Sato Y, et al. Blood flow restriction during low-intensity resistance exercise increases S6K1 phosphorylation and muscle protein synthesis. J Appl Physiol. 2007; 103: 903-10.
139. Baar K, Esser K. Phosphorylation of p70S6k correlates with increased skeletal muscle mass following resistance exercise. Am J Physiol Cell Physiol. 1999; 276: C120-7.
140. Wang XH, Du J, Klein JD, Bailey JL, Mitch WE. Exercise ameliorates chronic kidney disease-induced defects in muscle protein metabolism and progenitor cell function. Kidney Int. 2009; 76: 751-9.
141. Lenk K, Schur R, Linke A, Erbs S, Matsumoto Y, Adams V, et al. Impact of exercise training on myostatin expression in the myocardium and skeletal muscle in a chronic heart failure model. Eur J Heart Fail. 2009; 11: 342-8.
142. Vogiatzis I, Simoes DCM, Stratakos G, Kourepini E, Terzis G, Manta P, Athanasopoulos D, Roussos C, Wagner PD, Zakynthinos S. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. Eur Respir J. 2010; 36: 301-10.
143. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle. J Cachexia Sarcopenia Muscle. 2010. doi: 10. 1007/s13539-010-0003-5.